Cystatin C as an Early Marker of Contrast-Medium Nephropathy in Cardiac Catheterization Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00467311|
Recruitment Status : Completed
First Posted : April 30, 2007
Last Update Posted : May 8, 2008
Cystatin C compared with creatinine is a better and earlier marker of contrast-induced nephropathy in high and intermedium risk cardiac catheterization patients.
Establish if Cystatin C is superior detecting contrast-induced nephropathy than creatinine in high and intermedium risk cardiac catheterization patients.
|Condition or disease|
|Contrast Induced Nephropathy Acute Renal Failure|
Contrast induced-nephropathy is a complication that is underestimated in clinical practice after cardiac catheterization. During the last 30 years, because of the increasing use of contrast medium for diagnostic and therapeutic procedures, this has become the third in-hospital cause of acute renal failure (12%). That's why, it is necessary to establish an earlier marker of renal dysfunction that can help us in the diagnosis and allow us to initiate the appropriate therapeutics, because depending on the severity of the renal damage, it can increase the cardiovascular risk and morbidity.
The risk of contrast medium nephropathy is still present even with the use of low osmolarity contrast media, and many patients increase their in-hospital days, costs and hemodialysis requirement.
Cystatin C is a non glucosylated protein produced in nucleated cells in a constant rate, and because of its low molecular weight it's filtered through the glomerular membrane without restriction and it's fully reabsorbed in the proximal tubule, that's why it's considered an excellent marker evaluating the glomerular filtration rate in patients with acute renal failure during the first 24-48 hours.
We propose that Cystatin C can be useful as an earlier and superior marker of contrast-induced nephropathy in high and intermedium cardiac catheterization patients.
|Study Type :||Observational|
|Actual Enrollment :||66 participants|
|Official Title:||Diagnostic, Transversal, Comparative, Not Randomized Trial for the Evaluation of Cystatin C as an Early Marker of Contrast-Medium Nephropathy in High-and-Intermedium-Risk Patients Undergoing to Cardiac Catheterization|
|Study Start Date :||December 2006|
|Actual Primary Completion Date :||December 2007|
|Actual Study Completion Date :||April 2008|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00467311
|Ignacio Chávez National Institute of Cardiology|
|Mexico City, DF, Mexico, 01480|
|Principal Investigator:||Jhonathan L Uribe-González, MD, MSc||Ignacio Chávez National Institute of Cardiology|
|Study Chair:||Jorge G Hernández, MD, FSCAI||Ignacio Chávez National Institute of Cardiology|
|Study Director:||Marco A Martínez-Rios||Ignacio Chávez National Institute of Cardiology|
|Principal Investigator:||Marco A Peña-Duque, MD||Ignacio Chávez National Institute of Cardiology|